{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:08:27Z","timestamp":1793650107484,"version":"4.5.1"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI156766"],"award-info":[{"award-number":["R21 AI156766"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.addr.2022.114378","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T18:40:58Z","timestamp":1654368058000},"page":"114378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":229,"special_numbering":"C","title":["Novel antimicrobial agents for combating antibiotic-resistant bacteria"],"prefix":"10.1016","volume":"187","author":[{"given":"Rachel Yoon Kyung","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue C.","family":"Nang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114378_b0005","unstructured":"World Health Organisation, Global action plan on antimicrobial resistance, 2015."},{"key":"10.1016\/j.addr.2022.114378_b0010","unstructured":"Centers for Disease Control and Prevention, Antibiotic resistance threats in the United States, 2019."},{"key":"10.1016\/j.addr.2022.114378_b0015","unstructured":"J. O'Neill, Tackling drug-resistant infections globally: Final report and recmomendations, 2016."},{"key":"10.1016\/j.addr.2022.114378_b0020","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/IDR.S234610","article-title":"Antimicrobial resistance: Implications and costs","volume":"12","author":"Dadgostar","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"2022","key":"10.1016\/j.addr.2022.114378_b0025","first-page":"629","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.addr.2022.114378_b0030","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.addr.2022.114378_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41579-019-0311-5","article-title":"Phage diversity, genomics and phylogeny","volume":"18","author":"Dion","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.addr.2022.114378_b0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1111","article-title":"The prospect for bacteriophage therapy in Western medicine","volume":"2","author":"Merril","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114378_b0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.addr.2018.08.001","article-title":"Phage therapy for respiratory infections","volume":"133","author":"Chang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114378_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2017.09.002","article-title":"Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection","volume":"121","author":"Chang","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114378_b0055","first-page":"30047","article-title":"Topical application of bacteriophages for treatment of wound infections","volume":"S1931\u20135244","author":"Chang","year":"2020","journal-title":"Trans Res"},{"key":"10.1016\/j.addr.2022.114378_b0060","article-title":"Phage therapy with a focus on the human microbiota","volume":"8131","author":"Divya Ganeshan","year":"2019","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.addr.2022.114378_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-021-01026-9","article-title":"Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection","volume":"9","author":"Mu","year":"2021","journal-title":"Microbiome"},{"issue":"2","key":"10.1016\/j.addr.2022.114378_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and cons of phage therapy","volume":"1","author":"Loc-Carrillo","year":"2011","journal-title":"Bacteriophage"},{"issue":"3","key":"10.1016\/j.addr.2022.114378_b0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2022.114378_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.01.006","article-title":"The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice","author":"Chang","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2022.114378_b0085","series-title":"Bacteriophage therapy: From lab to clinical practice","first-page":"159","article-title":"Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials","author":"Fish","year":"2018"},{"key":"10.1016\/j.addr.2022.114378_b0090","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41467-022-29689-4","article-title":"Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection","volume":"13","author":"Little","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.addr.2022.114378_b0095","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114378_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","article-title":"Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients","volume":"21","author":"Chang","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2022.114378_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.33073\/pjm-2014-019","article-title":"Bacteriophages as an alternative strategy for fighting biofilm development","volume":"63","author":"Parasion","year":"2014","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.addr.2022.114378_b0110","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1128\/AAC.06480-11","article-title":"The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms","volume":"56","author":"Kirby","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/femsre\/fux010","article-title":"Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria","volume":"41","author":"Hall","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.addr.2022.114378_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/08927014.2015.1131821","article-title":"Discrimination of bacteriophage infected cells using locked nucleic acid fluorescent in situ hybridization (LNA-FISH)","volume":"32","author":"Vilas Boas","year":"2016","journal-title":"Biofouling"},{"issue":"4","key":"10.1016\/j.addr.2022.114378_b0125","doi-asserted-by":"crossref","first-page":"e18597","DOI":"10.1371\/journal.pone.0018597","article-title":"The T7-related Pseudomonas putida phage \u03c615 displays virion-associated biofilm degradation properties","volume":"6","author":"Cornelissen","year":"2011","journal-title":"PLoS ONE"},{"issue":"27","key":"10.1016\/j.addr.2022.114378_b0130","doi-asserted-by":"crossref","first-page":"11197","DOI":"10.1073\/pnas.0704624104","article-title":"Dispersing biofilms with engineered enzymatic bacteriophage","volume":"104","author":"Lu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.addr.2022.114378_b0135","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/AEM.67.6.2746-2753.2001","article-title":"Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms","volume":"67","author":"Hanlon","year":"2001","journal-title":"Appl. Environ. Microbiol."},{"issue":"1","key":"10.1016\/j.addr.2022.114378_b0140","doi-asserted-by":"crossref","first-page":"e0168615","DOI":"10.1371\/journal.pone.0168615","article-title":"Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms","volume":"12","author":"Chaudhry","year":"2017","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.addr.2022.114378_b0145","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.3390\/v6103778","article-title":"Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms","volume":"6","author":"Coulter","year":"2014","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.addr.2022.114378_b0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/antibiotics9050268","article-title":"Phages for biofilm removal","volume":"9","author":"Ferriol-Gonz\u00e1lez","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.addr.2022.114378_b0155","doi-asserted-by":"crossref","first-page":"e2261","DOI":"10.7717\/peerj.2261","article-title":"Phage on tap-a quick and efficient protocol for the preparation of bacteriophage laboratory stocks","volume":"4","author":"Bonilla","year":"2016","journal-title":"PeerJ"},{"key":"10.1016\/j.addr.2022.114378_b0160","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","article-title":"Standardized bacteriophage purification for personalized phage therapy","volume":"15","author":"Luong","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2022.114378_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120850","article-title":"Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages","volume":"605","author":"Chang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120200","article-title":"Phage cocktail powder for Pseudomonas aeruginosa respiratory infections","volume":"596","author":"Li","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0175","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114378_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121206","article-title":"Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections","volume":"609","author":"Khanal","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0185","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11095-017-2213-4","article-title":"Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, jet nebulizer, and soft mist inhaler","volume":"34","author":"Carrigy","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114378_b0190","doi-asserted-by":"crossref","first-page":"e01714","DOI":"10.1128\/AAC.01714-17","article-title":"Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation","volume":"62","author":"Chang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fcimb.2017.00049","article-title":"Long-term safety of topical bacteriophage application to the frontal sinus region","volume":"7","author":"Drilling","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/1462-2920.13574","article-title":"Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh","volume":"19","author":"Sarker","year":"2017","journal-title":"Environ. Microbiol."},{"issue":"3","key":"10.1016\/j.addr.2022.114378_b0205","doi-asserted-by":"crossref","first-page":"fnv242","DOI":"10.1093\/femsle\/fnv242","article-title":"Safety and efficacy of phage therapy via the intravenous route","volume":"363","author":"Speck","year":"2016","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.addr.2022.114378_b0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114378_b0215","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/thoraxjnl-2016-209265","article-title":"Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa","volume":"72","author":"Waters","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2022.114378_b0220","doi-asserted-by":"crossref","first-page":"e01470","DOI":"10.1128\/AAC.01470-20","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.addr.2022.114378_b0225","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cmi.2020.04.039","article-title":"Pharmacokinetics\/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a Proof-of-Concept study","volume":"26","author":"Lin","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"issue":"8","key":"10.1016\/j.addr.2022.114378_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01832-20","article-title":"Novel lytic phages protect cells and mice against Pseudomonas aeruginosa infection","volume":"95","author":"Chen","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2022.114378_b0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jgar.2019.05.005","article-title":"Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia","volume":"19","author":"Leshkasheli","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.addr.2022.114378_b0240","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1007\/s00284-020-02041-z","article-title":"Potential of a bacteriophage isolated from wastewater in treatment of lobar pneumonia infection induced by Klebsiella pneumoniae in mice","volume":"77","author":"Soleimani Sasani","year":"2020","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104317","article-title":"Identification of a novel phage targeting methicillin-resistant Staphylococcus aureus In vitro and In vivo","volume":"149","author":"Ji","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.addr.2022.114378_b0250","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/CCM.0000000000004352","article-title":"Nebulized bacteriophages for prophylaxis of experimental ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"48","author":"Prazak","year":"2020","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.addr.2022.114378_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.104744","article-title":"Locally isolated broad host-range bacteriophage kills methicillin-resistant Staphylococcus aureus in an in vivo skin excisional wound model in mice","volume":"152","author":"Shetru","year":"2021","journal-title":"Microb. Pathog."},{"issue":"9","key":"10.1016\/j.addr.2022.114378_b0260","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.02900-18","article-title":"Two novel bacteriophages improve survival in Galleria mellonella infection and mouse acute pneumonia models infected with extensively drug-resistant Pseudomonas aeruginosa","volume":"85","author":"Jeon","year":"2019","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0265","doi-asserted-by":"crossref","unstructured":"Re: Works published in CVIR by Robert A. Slutsky, M.D, Cardiovasc Intervent Radiol, 10 (1987) 52.","DOI":"10.1007\/BF02583311"},{"key":"10.1016\/j.addr.2022.114378_b0270","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1038\/s41598-020-62691-8","article-title":"Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates","volume":"10","author":"Horv\u00e1th","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114378_b0275","doi-asserted-by":"crossref","first-page":"11803","DOI":"10.1038\/s41598-020-68702-y","article-title":"Characterization of extended-spectrum-\u03b2-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo","volume":"10","author":"Wintachai","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114378_b0280","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.3390\/ijms21124390","article-title":"Antibiotics act with vB_AbaP_AGC01 phage against Acinetobacter baumannii in human heat-inactivated plasma blood and Galleria mellonella models","volume":"21","author":"Grygorcewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114378_b0285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fmicb.2020.00110","article-title":"Antibacterial efficacy of two commercially available bacteriophage formulations","volume":"11","author":"Tkhilaishvili","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/v11050411","article-title":"New bacteriophages against emerging lineages ST23 and ST258 of Klebsiella pneumoniae and efficacy assessment in Galleria mellonella larvae","volume":"11","author":"Thiry","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2022.114378_b0295","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/microorganisms7110556","article-title":"Combined use of the Ab105-2\u03c6\u0394CI lytic mutant phage and different antibiotics in clinical isolates of multi-resistant Acinetobacter baumannii","volume":"7","author":"Blasco","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.addr.2022.114378_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198348","article-title":"Identification and complete genome of lytic \u201cKp34likevirus\u201d phage vB_KpnP_Bp5 and therapeutic potency in the treatment of lethal Klebsiella pneumoniae infections in mice","volume":"297","author":"Zhang","year":"2021","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.addr.2022.114378_b0305","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00034-21","article-title":"Bacteriophage treatment rescues mice infected with multidrug-resistant Klebsiella pneumoniae ST258","volume":"12","author":"Hesse","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.addr.2022.114378_b0310","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-019-1443-5","article-title":"Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia","volume":"19","author":"Jeon","year":"2019","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105997","article-title":"Synergistic phage-surfactant combination clears IgE-promoted Staphylococcus aureus aggregation in vitro and enhances the effect in vivo","volume":"56","author":"Kim","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.addr.2022.114378_b0320","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/ph14030184","article-title":"Synergistic killing and re-sensitization of Pseudomonas aeruginosa to antibiotics by phage-antibiotic combination treatment","volume":"14","author":"Engeman","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.addr.2022.114378_b0325","doi-asserted-by":"crossref","first-page":"e0245354","DOI":"10.1371\/journal.pone.0245354","article-title":"Klebsiella virus UPM2146 lyses multiple drug-resistant Klebsiella pneumoniae in vitro and in vivo","volume":"16","author":"Assafiri","year":"2021","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.addr.2022.114378_b0330","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiy678","article-title":"Bacteriophage therapy increases complement-mediated lysis of bacteria and enhances bacterial clearance after acute lung infection with multidrug-resistant Pseudomonas aeruginosa","volume":"219","author":"Abd El-Aziz","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.addr.2022.114378_b0335","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fmb.13.47","article-title":"Phage cocktails and the future of phage therapy","volume":"8","author":"Chan","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/j.addr.2022.114378_b0340","doi-asserted-by":"crossref","first-page":"e00954","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0345","unstructured":"Yale Office of Cooperative Research. Yale\u2019s office of cooperative research granted \u201cSafe to Proceed\u201d notices to two INDs: COVID-19 related multi-Site clinical trial in the works. (2020) [cited 2021 9 March] Available from: https:\/\/ocr.yale.edu\/node\/51."},{"key":"10.1016\/j.addr.2022.114378_b0350","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fmicb.2015.00343","article-title":"Virulence reduction in bacteriophage resistant bacteria","volume":"6","author":"Le\u00f3n","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0355","doi-asserted-by":"crossref","first-page":"e03497","DOI":"10.7554\/eLife.03497","article-title":"Evolutionary consequences of intra-patient phage predation on microbial populations","volume":"3","author":"Seed","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.addr.2022.114378_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119952","article-title":"Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections","volume":"591","author":"Lin","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0365","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.09.024","article-title":"Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa","volume":"551","author":"Lin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0370","doi-asserted-by":"crossref","first-page":"e00461","DOI":"10.1128\/AAC.00461-20","article-title":"Bacteriophage-antibiotic combination strategy: an alternative against methicillin-resistant phenotypes of Staphylococcus aureus","volume":"64","author":"Kebriaei","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.addr.2022.114378_b0375","doi-asserted-by":"crossref","first-page":"e0220421","DOI":"10.1371\/journal.pone.0220421","article-title":"CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection","volume":"14","author":"Cobb","year":"2019","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.addr.2022.114378_b0380","doi-asserted-by":"crossref","first-page":"e0226574","DOI":"10.1371\/journal.pone.0226574","article-title":"Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus","volume":"14","author":"Morris","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114378_b0385","doi-asserted-by":"crossref","first-page":"e00468","DOI":"10.1128\/AEM.00468-21","article-title":"Aminoglycosides antagonize bacteriophage proliferation, attenuating phage suppression of bacterial growth, biofilm formation, and antibiotic resistance","volume":"87","author":"Zuo","year":"2021","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0390","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/antibiotics11050570","article-title":"Phage-antibiotic therapy as a promising strategy to combat multidrug-resistant infections and to enhance antimicrobial efficiency","volume":"11","author":"Liu","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.addr.2022.114378_b0395","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tim.2015.12.011","article-title":"Evolutionary rationale for phages as complements of antibiotics","volume":"24","author":"Torres-Barcel\u00f3","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000799","article-title":"Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth","volume":"2","author":"Comeau","year":"2007","journal-title":"PLoS ONE"},{"issue":"22","key":"10.1016\/j.addr.2022.114378_b0405","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.02085-18","article-title":"Phage-antibiotic synergy via delayed lysis","volume":"84","author":"Kim","year":"2018","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0410","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fmicb.2018.00127","article-title":"Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms","volume":"9","author":"Kumaran","year":"2018","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.addr.2022.114378_b0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jbiotec.2004.08.003","article-title":"Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7","volume":"115","author":"Yoichi","year":"2005","journal-title":"J. Biotechnol."},{"issue":"7","key":"10.1016\/j.addr.2022.114378_b0420","doi-asserted-by":"crossref","first-page":"e68562","DOI":"10.1371\/journal.pone.0068562","article-title":"Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004","volume":"8","author":"Le","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114378_b0425","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/JB.185.3.1037-1044.2003","article-title":"pIIICTX, a predicted CTX\u03c6 minor coat protein, can expand the host range of coliphage fd to include Vibrio cholerae","volume":"185","author":"Heilpern Andrew","year":"2003","journal-title":"J. Bacteriol."},{"issue":"3","key":"10.1016\/j.addr.2022.114378_b0430","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cels.2015.08.013","article-title":"Engineering modular viral scaffolds for targeted bacterial population editing","volume":"1","author":"Ando","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.addr.2022.114378_b0435","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/s41598-021-81580-2","article-title":"Designing P. aeruginosa synthetic phages with reduced genomes","volume":"11","author":"Pires","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114378_b0440","doi-asserted-by":"crossref","first-page":"44929","DOI":"10.1038\/srep44929","article-title":"Genetic engineering of a temperate phage-based delivery system for CRISPR\/Cas9 antimicrobials against Staphylococcus aureus","volume":"7","author":"Park","year":"2017","journal-title":"Sci. Rep."},{"issue":"31","key":"10.1016\/j.addr.2022.114378_b0445","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1073\/pnas.2001888117","article-title":"High-throughput discovery of phage receptors using transposon insertion sequencing of bacteria","volume":"117","author":"Kortright","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2022.114378_b0450","doi-asserted-by":"crossref","first-page":"13981","DOI":"10.1038\/s41598-020-70841-1","article-title":"Optimizing bacteriophage engineering through an accelerated evolution platform","volume":"10","author":"Favor","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.addr.2022.114378_b0455","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/bact.1.2.15845","article-title":"Phage treatment of human infections","volume":"1","author":"Abedon","year":"2011","journal-title":"Bacteriophage"},{"issue":"7","key":"10.1016\/j.addr.2022.114378_b0460","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.burns.2017.03.029","article-title":"Liposome loaded phage cocktail: Enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections","volume":"43","author":"Chadha","year":"2017","journal-title":"Burns"},{"key":"10.1016\/j.addr.2022.114378_b0465","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3389\/fmicb.2018.02172","article-title":"Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing","volume":"9","author":"Cinquerrui","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0470","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","article-title":"Formulation, stabilisation and encapsulation of bacteriophage for phage therapy","volume":"249","author":"Malik","year":"2017","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2022.114378_b0475","doi-asserted-by":"crossref","first-page":"101754","DOI":"10.1016\/j.jddst.2020.101754","article-title":"The effects of surface properties of liposomes on their activity against Pseudomonas aeruginosa PAO-1 biofilm","volume":"57","author":"Ibaraki","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.addr.2022.114378_b0480","doi-asserted-by":"crossref","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","article-title":"Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection","volume":"5","author":"LaVergne","year":"2018","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.addr.2022.114378_b0485","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination","volume":"69","author":"Nir-Paz","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.addr.2022.114378_b0490","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report","volume":"169","author":"Hoyle","year":"2018","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0495","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.addr.2022.114378_b0500","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","article-title":"Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients","volume":"10","author":"Wu","year":"2021","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.addr.2022.114378_b0505","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.addr.2022.114378_b0510","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10159","article-title":"Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization","volume":"5","author":"Chang","year":"2020","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2022.114378_b0515","doi-asserted-by":"crossref","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive Cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.addr.2022.114378_b0520","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s11095-016-1892-6","article-title":"Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections","volume":"33","author":"Leung","year":"2016","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.addr.2022.114378_b0525","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41564-020-00830-7","article-title":"Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials","volume":"6","author":"Gordillo Altamirano","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0530","doi-asserted-by":"crossref","first-page":"35","DOI":"10.20953\/1729-9225-2017-1-35-40","article-title":"Anti-phage antibody response in phage therapy against healthcare-associated infections (HAIs)","volume":"15","author":"Bochkareva","year":"2017","journal-title":"Infekc Bolezni"},{"key":"10.1016\/j.addr.2022.114378_b0535","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/v13091785","article-title":"Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation","volume":"13","author":"Paul","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2022.114378_b0540","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14712598.2019.1651287","article-title":"The fall and rise of phage therapy in modern medicine","volume":"19","author":"G\u00f3rski","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2022.114378_b0545","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12223-020-00835-z","article-title":"Anti-phage serum antibody responses and the outcome of phage therapy","volume":"66","author":"\u0141usiak-Szelachowska","year":"2021","journal-title":"Folia Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0550","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/v11010018","article-title":"Clinical indications and compassionate use of phage therapy: Personal experience and literature review with a focus on osteoarticular infections","volume":"11","author":"Patey","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2022.114378_b0555","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/cid\/cix184","article-title":"The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by \u03b2-lactams","volume":"64","author":"Dufour","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2022.114378_b0560","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s00253-018-8811-1","article-title":"Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?","volume":"102","author":"Maciejewska","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2022.114378_b0565","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-2180-13-53","article-title":"phiBIOTICS: catalogue of therapeutic enzybiotics, relevant research studies and practical applications","volume":"13","author":"Hojckova","year":"2013","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0570","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.03560-14","article-title":"Identification of capsular types in carbapenem-resistant Klebsiella pneumoniae strains by wzc sequencing and implications for capsule depolymerase treatment","volume":"59","author":"Pan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0575","doi-asserted-by":"crossref","unstructured":"C. Cassino, M. Murphy, J. Boyle, J. Rotolo, M. Wittekind, Results of the first in human study of lysin CF-301 evaluating the safety, tolerability and pharmacokinetic profile in healthy volunteers, in: Proceedings of the 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands, 2016, pp. 9-12.","DOI":"10.26226\/morressier.56ebbf52d462b80296c97eca"},{"key":"10.1016\/j.addr.2022.114378_b0580","doi-asserted-by":"crossref","first-page":"e02629","DOI":"10.1128\/AAC.02629-16","article-title":"Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers","volume":"61","author":"Jun","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114066","article-title":"Advances in the development of antimicrobial peptides and proteins for inhaled therapy","volume":"180","author":"Wang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114378_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.748718","article-title":"Discovering the potentials of four phage endolysins to combat Gram-negative infections","volume":"12","author":"Vasina","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0595","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1073\/pnas.061038398","article-title":"Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme","volume":"98","author":"Nelson","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2022.114378_b0600","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/153537020623100402","article-title":"Bacteriophage endolysins as a novel class of antibacterial agents","volume":"231","author":"Borysowski","year":"2006","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.addr.2022.114378_b0605","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1126\/science.1066869","article-title":"Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase","volume":"294","author":"Loeffler","year":"2001","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.addr.2022.114378_b0610","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tim.2005.08.007","article-title":"Bacteriophage lytic enzymes: novel anti-infectives","volume":"13","author":"Fischetti","year":"2005","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0615","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/1751-7915.13594","article-title":"The endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activity","volume":"14","author":"Yuan","year":"2021","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.addr.2022.114378_b0620","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fmicb.2017.00293","article-title":"A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa","volume":"8","author":"Guo","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0625","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1007\/s00253-021-11366-z","article-title":"Characterization of a broad-spectrum endolysin LysSP1 encoded by a Salmonella bacteriophage","volume":"105","author":"Jiang","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2022.114378_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodcont.2021.108460","article-title":"Application of endolysin LysSTG2 as a potential biocontrol agent against planktonic and biofilm cells of Pseudomonas on various food and food contact surfaces","volume":"131","author":"Zhang","year":"2022","journal-title":"Food Control"},{"key":"10.1016\/j.addr.2022.114378_b0635","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1365-2672.2010.04931.x","article-title":"Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa","volume":"110","author":"Briers","year":"2011","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0640","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1128\/AAC.04641-14","article-title":"Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model","volume":"59","author":"Lood","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0645","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00253-011-3104-y","article-title":"Antibacterial activity of Acinetobacter baumannii phage \u03d5AB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria","volume":"90","author":"Lai","year":"2011","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2022.114378_b0650","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.637313","article-title":"A novel Acinetobacter baumannii bacteriophage endolysin LysAB54 with high antibacterial activity against multiple Gram-negative microbes","volume":"11","author":"Khan","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036991","article-title":"Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201\u03c62-1 and PVP-SE1","volume":"7","author":"Walmagh","year":"2012","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.addr.2022.114378_b0660","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01379-14","article-title":"Engineered endolysin-based \u201cArtilysins\u201d to combat multidrug-resistant gram-negative pathogens","volume":"5","author":"Briers","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.addr.2022.114378_b0665","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/v12111340","article-title":"LysSAP26, a new recombinant phage endolysin with a broad spectrum antibacterial activity","volume":"12","author":"Kim","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2022.114378_b0670","article-title":"Characterization of MSlys, the endolysin of Streptococcus pneumoniae phage MS1","volume":"28","author":"Silva","year":"2020","journal-title":"Biotechnol. Rep,"},{"key":"10.1016\/j.addr.2022.114378_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.fm.2019.103245","article-title":"Effective removal of staphylococcal biofilms on various food contact surfaces by Staphylococcus aureus phage endolysin LysCSA13","volume":"84","author":"Cha","year":"2019","journal-title":"Food Microbiol."},{"issue":"3","key":"10.1016\/j.addr.2022.114378_b0680","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00546-21","article-title":"Design SMAP29-LysPA26 as a highly efficient Artilysin against Pseudomonas aeruginosa with bactericidal and antibiofilm activity","volume":"9","author":"Wang","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.addr.2022.114378_b0685","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/v12050545","article-title":"Antibiofilm activity of a broad-range recombinant endolysin LysECD7: in vitro and in vivo study","volume":"12","author":"Fursov","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2022.114378_b0690","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/mdr.2012.0025","article-title":"Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus","volume":"18","author":"Fernandes","year":"2012","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.addr.2022.114378_b0695","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1128\/AEM.01831-08","article-title":"Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci","volume":"75","author":"Horgan","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0700","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/1574-6968.12104","article-title":"Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme","volume":"342","author":"Mao","year":"2013","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.addr.2022.114378_b0705","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3389\/fmicb.2018.02927","article-title":"Improved biodistribution and extended serum half-life of a bacteriophage endolysin by albumin binding domain fusion","volume":"9","author":"Seijsing","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0710","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00253-006-0771-1","article-title":"Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci","volume":"74","author":"Cheng","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2022.114378_b0715","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijantimicag.2011.08.009","article-title":"A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance","volume":"38","author":"Resch","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.addr.2022.114378_b0720","doi-asserted-by":"crossref","first-page":"e00209","DOI":"10.1128\/mBio.00209-20","article-title":"Targeting hidden pathogens: cell-penetrating enzybiotics eradicate intracellular drug-resistant Staphylococcus aureus","volume":"11","author":"R\u00f6hrig","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.addr.2022.114378_b0725","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1038\/s41598-020-68983-3","article-title":"Exploiting phage receptor binding proteins to enable endolysins to kill Gram-negative bacteria","volume":"10","author":"Zampara","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114378_b0730","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3389\/fmicb.2018.01033","article-title":"Thousands of novel endolysins discovered in uncultured phage genomes","volume":"9","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0735","doi-asserted-by":"crossref","first-page":"118850","DOI":"10.1016\/j.ijpharm.2019.118850","article-title":"Comprehensive evaluation of chitosan nanoparticle based phage lysin delivery system; a novel approach to counter S. pneumoniae infections","volume":"573","author":"Gondil","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0740","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1208\/s12249-020-01763-4","article-title":"Exploring endolysin-loaded alginate-chitosan nanoparticles as future remedy for Staphylococcal infections","volume":"21","author":"Kaur","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.addr.2022.114378_b0745","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/antibiotics9050242","article-title":"Encapsulation of the Antistaphylococcal endolysin LysRODI in pH-sensitive liposomes","volume":"9","author":"Portilla","year":"2020","journal-title":"Antibiotics"},{"issue":"4","key":"10.1016\/j.addr.2022.114378_b0750","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12602-010-9047-2","article-title":"A comparative study between the antibacterial effect of nisin and nisin-loaded chitosan\/alginate nanoparticles on the growth of Staphylococcus aureus in raw and pasteurized milk samples","volume":"2","author":"Zohri","year":"2010","journal-title":"Probiotics Antimicrob Proteins"},{"key":"10.1016\/j.addr.2022.114378_b0755","doi-asserted-by":"crossref","first-page":"e02176","DOI":"10.1128\/AAC.02176-19","article-title":"Synergistic activity of Exebacase (CF-301) in addition to daptomycin against Staphylococcus aureus in a neutropenic murine thigh infection model","volume":"64","author":"Asempa","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.addr.2022.114378_b0760","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acsinfecdis.0c00812","article-title":"Development of advanced chimeric endolysin to control multidrug-resistant Staphylococcus aureus through domain shuffling","volume":"7","author":"Lee","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.addr.2022.114378_b0765","doi-asserted-by":"crossref","first-page":"e00311","DOI":"10.1128\/AAC.00311-20","article-title":"A choline-recognizing monomeric lysin, ClyJ-3m, shows elevated activity against Streptococcus pneumoniae","volume":"64","author":"Luo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0770","doi-asserted-by":"crossref","first-page":"e02043","DOI":"10.1128\/AAC.02043-18","article-title":"ClyJ Is a novel Pneumococcal chimeric lysin with a cysteine- and histidine-dependent amidohydrolase\/peptidase catalytic domain","volume":"63","author":"Yang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0775","doi-asserted-by":"crossref","first-page":"e02009","DOI":"10.1128\/AAC.02009-18","article-title":"Efficacy of intranasal administration of the recombinant endolysin SAL200 in a lethal murine Staphylococcus aureus pneumonia model","volume":"63","author":"Bae","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0780","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1038\/s41598-020-64145-7","article-title":"In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens","volume":"10","author":"Blasco","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114378_b0785","doi-asserted-by":"crossref","first-page":"e00024","DOI":"10.1128\/AAC.00024-19","article-title":"Isolation of phage lysins that effectively kill Pseudomonas aeruginosa in mouse models of lung and skin infection","volume":"63","author":"Raz","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0790","doi-asserted-by":"crossref","unstructured":"B.R. Sosa, Y. Niu, K. Turajane, K. Staats, V. Suhardi, A. Carli, V. Fischetti, M. Bostrom, X. Yang, 2020 John Charnley Award: The antimicrobial potential of bacteriophage-derived lysin in a murine debridement, antibiotics, and implant retention model of prosthetic joint infection, Bone Joint J., 102-b (2020) 3-10.","DOI":"10.1302\/0301-620X.102B7.BJJ-2019-1590.R1"},{"key":"10.1016\/j.addr.2022.114378_b0795","doi-asserted-by":"crossref","first-page":"e00482","DOI":"10.1128\/AAC.00482-20","article-title":"Effect of the lysin Exebacase on cardiac vegetation progression in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis as determined by echocardiography","volume":"64","author":"Shah","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0800","doi-asserted-by":"crossref","first-page":"e01235","DOI":"10.1128\/AAC.01235-19","article-title":"Exebacase in addition to daptomycin Is more active than daptomycin or Exebacase alone in methicillin-resistant Staphylococcus aureus osteomyelitis in rats","volume":"63","author":"Karau","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.addr.2022.114378_b0805","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02723-20","article-title":"Exebacase is active In vitro in pulmonary surfactant and is efficacious alone and synergistic with daptomycin in a mouse model of lethal Staphylococcus aureus lung infection","volume":"65","author":"Swift","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0810","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1128\/IAI.71.11.6199-6204.2003","article-title":"Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia","volume":"71","author":"Loeffler","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2022.114378_b0815","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1128\/CMR.15.1.95-110.2002","article-title":"Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis","volume":"15","author":"Nau","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2022.114378_b0820","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1128\/AAC.49.11.4789-4792.2005","article-title":"Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats","volume":"49","author":"Entenza","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0825","unstructured":"Micreos. Welcome to the world of Micreos. (2021) [cited 2021 9 March] Available from: https:\/\/www.micreos.com\/."},{"key":"10.1016\/j.addr.2022.114378_b0830","doi-asserted-by":"crossref","first-page":"e02291","DOI":"10.1128\/AAC.02291-18","article-title":"The Antistaphylococcal lysin, CF-301, activates key host factors in human blood to potentiate methicillin-resistant Staphylococcus aureus bacteriolysis","volume":"63","author":"Indiani","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0835","doi-asserted-by":"crossref","first-page":"e02666","DOI":"10.1128\/AAC.02666-16","article-title":"Bacteriophage lysin CF-301, a potent Antistaphylococcal biofilm agent","volume":"61","author":"Schuch","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0840","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/infdis\/jit637","article-title":"Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia","volume":"209","author":"Schuch","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2022.114378_b0845","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1073\/pnas.1717160115","article-title":"Technologies to address antimicrobial resistance","volume":"115","author":"Baker","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2022.114378_b0850","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","article-title":"Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases","volume":"67","author":"Irani","year":"2015","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.addr.2022.114378_b0855","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0167-5699(00)01719-9","article-title":"Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA","volume":"21","author":"Krieg","year":"2000","journal-title":"Immunol. Today"},{"key":"10.1016\/j.addr.2022.114378_b0860","first-page":"1","article-title":"Bacterial extracts as immunomodulators for the prevention of recurrent respiratory infections in children","volume":"3","author":"Giovannini","year":"2014","journal-title":"J. Med. Microbiol. Diagn."},{"issue":"2","key":"10.1016\/j.addr.2022.114378_b0865","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2478\/cipms-2019-0016","article-title":"Liposomal-lipopolysaccharide vaccine extracted from Proteus mirabilis induces moderate TLR4 and CD14 production","volume":"32","author":"Nile","year":"2019","journal-title":"Curr. Issues Pharm. Medical Sci."},{"issue":"9","key":"10.1016\/j.addr.2022.114378_b0870","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s11427-012-4368-x","article-title":"Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis","volume":"55","author":"Zhang","year":"2012","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.addr.2022.114378_b0875","doi-asserted-by":"crossref","first-page":"e02588","DOI":"10.1128\/AAC.02588-18","article-title":"A Phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus thiomab antibody-antibiotic conjugate, in healthy volunteers","volume":"63","author":"Peck","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0880","unstructured":"Centauri Therapeutics. Alphamer platform. (2019) [cited 2021 9 March] Available from: http:\/\/www.centauritherapeutics.com\/index.php\/our-science\/our-science-2."},{"key":"10.1016\/j.addr.2022.114378_b0885","unstructured":"Beam Alliance. CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria. (2020) [cited 2021 9 March] Available from: https:\/\/beam-alliance.eu\/carb-x-backs-centauri-to-advance-a-new-platform-that-combines-antibiotic-power-with-the-ability-to-boost-the-immune-system-to-fight-infections-caused-by-drug-resistant-bacteria\/."},{"key":"10.1016\/j.addr.2022.114378_b0890","unstructured":"Cellics Therapeutics. Macrophage Nanosponge (M\u03a6-NS). (2021) [cited 2021 9 March] Available from: https:\/\/cellics.com\/macrophage-nanosponge\/."},{"key":"10.1016\/j.addr.2022.114378_b0895","unstructured":"N. DeFeudis. UC San Diego spinout awarded up to $15M for nanosponge designed to soak up sepsis-causing toxins. (2020) [cited 2021 9 March] Available from: https:\/\/endpts.com\/uc-san-diego-spinout-awarded-up-to-15m-for-nanosponge-designed-to-soak-up-sepsis-causing-toxins\/."},{"key":"10.1016\/j.addr.2022.114378_b0900","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1128\/AAC.02588-15","article-title":"A high-affinity native human antibody disrupts biofilm from Staphylococcus aureus bacteria and potentiates antibiotic efficacy in a mouse implant infection model","volume":"60","author":"Estell\u00e9s","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0905","unstructured":"Clarametyx Biosciences. Our Science. (2021) [cited 2021 9 March] Available from: https:\/\/clarametyx.com\/our-science\/."},{"key":"10.1016\/j.addr.2022.114378_b0910","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/antibiotics11010104","article-title":"Crumbling the castle: targeting DNABII proteins for collapsing bacterial biofilms as a therapeutic approach to treat disease and combat antimicrobial resistance","volume":"11","author":"Rogers","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.addr.2022.114378_b0915","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s10096-014-2156-1","article-title":"Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia","volume":"33","author":"Que","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2022.114378_b0920","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial","volume":"40","author":"Fran\u00e7ois","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.addr.2022.114378_b0925","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","article-title":"KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa","volume":"17","author":"Jain","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"11","key":"10.1016\/j.addr.2022.114378_b0930","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1128\/JCM.42.11.5229-5237.2004","article-title":"Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis","volume":"42","author":"Jain","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.addr.2022.114378_b0935","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1128\/AAC.02101-13","article-title":"Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii","volume":"58","author":"Smani","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.addr.2022.114378_b0940","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1021\/pr050143q","article-title":"Identification of an OprD homologue in Acinetobacter baumannii","volume":"4","author":"Dupont","year":"2005","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.addr.2022.114378_b0945","unstructured":"Businesswire. BiomX announces positive results of a Phase 1a pharmacokinetic study for inflammatory bowel disease\/primary sclerosing cholangitis (IBD\/PSC) evaluating delivery of oral BX002 phage therapy. (2021) [cited 2021 9 March] Available from: https:\/\/www.businesswire.com\/news\/home\/20210202005228\/en\/BiomX-Announces-Positive-Results-of-a-Phase-1a-Pharmacokinetic-Study-for-Inflammatory-Bowel-DiseasePrimary-Sclerosing-Cholangitis-IBDPSC-Evaluating-Delivery-of-Oral-BX002-Phage-Therapy."},{"key":"10.1016\/j.addr.2022.114378_b0950","unstructured":"GlobeNewswire. Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy. (2021) [cited 2021 9 March] Available from: https:\/\/www.globenewswire.com\/news-release\/2021\/02\/24\/2181504\/0\/en\/Locus-Biosciences-completes-first-of-its-kind-controlled-clinical-trial-for-CRISPR-enhanced-bacteriophage-therapy.html."},{"key":"10.1016\/j.addr.2022.114378_b0955","unstructured":"Amarta Pharmaceuticals. AmpliPhi Biosciences reports 2016 fourth-quarter and full-year results and provides corporate highlights. (2021) Available from: https:\/\/investor.armatapharma.com\/2017-03-27-AmpliPhi-Biosciences-Reports-2016-Fourth-Quarter-and-Full-Year-Results-and-Provides-Corporate-Highlights."},{"issue":"237\u2013238","key":"10.1016\/j.addr.2022.114378_b0960","first-page":"233","article-title":"Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial","volume":"18","author":"Rhoads","year":"2009","journal-title":"J. Wound Care"},{"key":"10.1016\/j.addr.2022.114378_b0965","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","article-title":"Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model","volume":"21","author":"Anand","year":"2020","journal-title":"J. Glob Antimicrob Resist"},{"key":"10.1016\/j.addr.2022.114378_b0970","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.613356","article-title":"Safety and efficacy of a phage, kpssk3, in an in vivo model of carbapenem-resistant hypermucoviscous Klebsiella pneumoniae bacteremia","volume":"12","author":"Shi","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114378_b0975","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbm.a.36790","article-title":"Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo","volume":"108","author":"Wroe","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2022.114378_b0980","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2018.12.002","article-title":"Safety and efficacy of a bacteriophage cocktail in an in vivo model of Pseudomonas aeruginosa sinusitis","volume":"206","author":"Fong","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2022.114378_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118779","article-title":"A novel wound dressing consisting of PVA-SA hybrid hydrogel membrane for topical delivery of bacteriophages and antibiotics","volume":"572","author":"Kaur","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114378_b0990","doi-asserted-by":"crossref","first-page":"e01870","DOI":"10.1128\/AAC.01870-19","article-title":"Efficacy of bacteriophages in a Staphylococcus aureus nondiabetic or diabetic foot infection murine model","volume":"64","author":"Albac","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b0995","article-title":"Combination therapy of phage vB_KpnM_P-KP2 and gentamicin combats acute pneumonia caused by K47 serotype Klebsiella pneumoniae","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Microbiol."},{"issue":"12","key":"10.1016\/j.addr.2022.114378_b1000","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.3390\/ijms21124390","article-title":"Antibiotics act with vB_AbaP_AGC01 phage against Acinetobacter baumannii in human heat-inactivated plasma blood and Galleria mellonella models","volume":"21","author":"Grygorcewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114378_b1005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/antibiotics10040461","article-title":"A highly active chimeric lysin with a calcium-enhanced bactericidal activity against Staphylococcus aureus in vitro and in vivo","volume":"10","author":"Li","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.addr.2022.114378_b1010","doi-asserted-by":"crossref","first-page":"e01707","DOI":"10.1128\/AAC.01707-20","article-title":"Deimmunized lysostaphin synergizes with small-molecule chemotherapies and resensitizes methicillin-resistant Staphylococcus aureus to \u03b2-lactam antibiotics","volume":"65","author":"Fang","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114378_b1015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/v11090769","article-title":"Therapeutic potential of an endolysin derived from Kayvirus S25\u20133 for Staphylococcal Impetigo","volume":"11","author":"Imanishi","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2022.114378_b1020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jgar.2020.01.005","article-title":"Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"22","author":"Kim","year":"2020","journal-title":"J. Glob Antimicrob Resist"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2200268X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2200268X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:29:37Z","timestamp":1759210177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X2200268X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":204,"alternative-id":["S0169409X2200268X"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114378","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antimicrobial agents for combating antibiotic-resistant bacteria","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114378"}}